RDEA119 and Sorafenib Combination Dose Escalation Study

NCT00785226 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Cancer

Interventions

DRUG: RDEA119
DRUG: Sorafenib

Sponsor

Bayer